About PreciseDx
Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading. As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $11,000,000 · Series-B+
- Capital Raise
Raised $20,700,000 · Series-B+
startupintros.com
- Capital Raise
Raised $10,750,000 · Series-A
fundraisingfox.com
- Milestone
Website domain registered
precisedx.ai
Investors & Backers
Funding History
Founders & Leadership
Bradley Gendell
Chief Financial Officer
Carlos Cordon-Cardo
Founder
Ed Sitar
Chief Financial Officer
Eric Converse
CEO
Gerardo Fernandez
Co-Founder
Jack Zeineh
Founder
Michael Donovan
Co-Founder
Wayne Brinster
President & CEO
Press Coverage & Sources
citybiz.co/article/708301/precisedx-raises-11m-eric-converse-appointed-ceo/
startupintros.com/news/2024-08-21-precisedx-series-b
fundraisingfox.com/companies/precisedx
prnewswire.com/news-releases/precisedx-raises-10-75-million-series-a-preferred-from-healthcare-industry-leaders-to-commercialize-cancer-risk-stratification-services-to-support-better-patient-insights-and-outcomes-301457862.html
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Hexagon Bio
hexagonbio.com
RefloDx
reflodx.com
HeyVoli
heyvoli.com
CureBay
curebay.com
4Tissue
4tissue.com